Mounjaro Maintenance: The Ultimate Guide & Best UK Pharmacies

Issues With Maintenance Pharmacies: When a Prescription Is Stopped

This section covers a problem Monj hears about more than any other on the maintenance topic: a pharmacy ends a Mounjaro or Wegovy prescription at a set BMI, a set time limit, or when weight loss plateaus, without a taper, a written explanation or a route to appeal. It explains what UK guidance actually says, what the clinical evidence shows about stopping, and what you can do before you join a provider and after a decision goes against you. It is consumer-protection information, not medical advice.

What a maintenance cut-off looks like

Four patterns come up repeatedly in reports sent to Monj and in public patient forums. Monj does not name individual pharmacies here because policies change and individual accounts cannot be independently verified. The patterns are:

• BMI cliff edge. Prescribing stops the moment BMI falls below a fixed number, sometimes in the low 20s, with no maintenance dose offered.
• Time limit. Treatment ends at a fixed duration, most often two years, whatever the patient’s response or regain risk.
• Plateau stop. Supply is withdrawn because weight loss has slowed, which is treated as the goal being reached rather than as the maintenance phase beginning.
• Silent stop. An order is declined or paused without an explanation, a taper plan or a named clinician to speak to.

What UK guidance actually says

The two-year rule is an NHS commissioning limit, not a clinical ceiling. NICE TA875 recommends semaglutide (Wegovy) on the NHS only within a specialist weight management service and for a maximum of two years. NICE’s own committee papers explain that the limit reflects how long people typically stay in those services and the absence of longer trial data at the time, and note that longer use could be considered as evidence emerges. A private pharmacy that stops at two years because of NICE is applying an NHS funding rule to a self-funded patient.

The licence does not set an exit BMI. The BMI thresholds in the Mounjaro and Wegovy licences (BMI of 30 or more, or 27 or more with a weight-related condition) are entry criteria for starting treatment. Neither licence instructs prescribers to stop at a particular BMI once weight has been lost. A pharmacy that uses a BMI floor is applying its own policy, which it is allowed to do, but it should say so up front.

Each supply must be an individual clinical decision. The General Pharmaceutical Council’s guidance for pharmacies providing services at a distance, updated on 4 February 2025, added weight-management medicines to its list of high-risk medicines. Prescribers must independently verify weight, height and BMI rather than rely on a questionnaire, must use timely two-way communication with the patient, and must consider ongoing monitoring and continuity of care for medicines used long term. An automatic cut-off applied without a conversation sits uneasily with that guidance.

What the evidence says about stopping

The strongest data comes from SURMOUNT-4, a randomised withdrawal trial published in JAMA in 2024 by Louis Aronne and colleagues. After 36 weeks of tirzepatide, participants were randomised either to continue or to switch to placebo for 52 weeks. Those who continued lost a further 5.5% of body weight on average; those who switched to placebo regained 14.0%. A post hoc analysis of the same trial, published in JAMA Internal Medicine in 2026 by Deborah Horn and colleagues, found that most participants who stopped regained 25% or more of the weight they had lost within a year, and that the improvements in blood pressure, lipids and blood sugar reversed in step with the regain.

The trial authors describe obesity as a chronic condition that, like type 2 diabetes or hypertension, usually needs long-term management. That does not mean everyone must stay on medication indefinitely. It does mean that an abrupt stop, with no taper and no maintenance plan, is the option with the worst evidence behind it.

Five questions to ask before you join a pharmacy

1. Is there a BMI below which you will no longer prescribe? What is it, and is it written in your terms?
2. Is there a maximum treatment duration? If so, what happens at the end?
3. Do you offer a maintenance or reduced dose, and a taper plan, when a patient reaches their goal?
4. If a prescriber declines an order, will I get a written reason and a named clinician to discuss it with?
5. If I want to move to another provider, will you send my treatment summary to them or to my GP?

Put the answers in an email so you have them in writing. The pharmacy directory above records the joining and maintenance BMI each pharmacy has stated to Monj, and whether it applies a time limit.

If your prescription has been stopped

• Ask for the reason in writing. A prescribing decision should be explainable. Ask whether it is a clinical judgement about you or a blanket policy.
• Ask about a taper or maintenance dose. If the answer is no, ask why, and ask for a treatment summary you can take elsewhere.
• Speak to your GP. NHS eligibility for these medicines is narrower than private eligibility, but your GP can record what has happened, advise on regain risk and refer you if you meet NHS criteria.
• Switch, but do it in order. Get the treatment summary first, then apply to a provider whose maintenance policy you have checked. Monj’s guide to switching pharmacy covers the practical steps.
• Complain if the process was poor. Start with the pharmacy’s own complaints procedure. If you are not satisfied, or if you believe there was no individual clinical assessment, you can raise a concern with the General Pharmaceutical Council.
• Tell Monj. Reports of blanket cut-offs help keep the maintenance policies in the directory accurate. Use the contact page.